Comparison of two protocols of blastocyst biopsy submitted to preimplantation genetic testing for aneuploidies: a randomized controlled trial

2019 ◽  
Vol 299 (5) ◽  
pp. 1487-1493 ◽  
Author(s):  
Haibin Zhao ◽  
Wenrong Tao ◽  
Mei Li ◽  
Hui Liu ◽  
Keliang Wu ◽  
...  
The Breast ◽  
2017 ◽  
Vol 36 ◽  
pp. 79-85 ◽  
Author(s):  
Kerry A. Sherman ◽  
Christopher J. Kilby ◽  
Laura-Kate Shaw ◽  
Caleb Winch ◽  
Judy Kirk ◽  
...  

Cancer ◽  
2016 ◽  
Vol 122 (22) ◽  
pp. 3509-3518 ◽  
Author(s):  
Charles W. Drescher ◽  
J. David Beatty ◽  
Robert Resta ◽  
M. Robyn Andersen ◽  
Kate Watabayashi ◽  
...  

2021 ◽  
Vol 10 (17) ◽  
pp. 3895
Author(s):  
Wei-Hui Shi ◽  
Zi-Ru Jiang ◽  
Zhi-Yang Zhou ◽  
Mu-Jin Ye ◽  
Ning-Xin Qin ◽  
...  

Background: Preimplantation genetic testing for aneuploidies (PGT-A) is widely used in women of advanced maternal age (AMA). However, the effectiveness remains controversial. Method: We conducted a comprehensive literature review comparing outcomes of IVF with or without PGT-A in women of AMA in PubMed, Embase, and the Cochrane Central Register of Controlled Trials in January 2021. All included trials met the criteria that constituted a randomized controlled trial for PGT-A involving women of AMA (≥35 years). Reviews, conference abstracts, and observational studies were excluded. The primary outcome was the live birth rate in included random control trials (RCTs). Results: Nine randomized controlled trials met our inclusion criteria. For techniques of genetic analysis, three trials (270 events) performed with comprehensive chromosomal screening showed that the live birth rate was significantly higher in the women randomized to IVF/ICSI with PGT-A (RR = 1.30, 95% CI 1.03–1.65), which was not observed in six trials used with FISH as well as all nine trials. For different stages of embryo biopsy, only the subgroup of blastocyst biopsy showed a higher live birth rate in women with PGT-A (RR = 1.36, 95% CI 1.04–1.79). Conclusion: The application of comprehensive chromosome screening showed a beneficial effect of PGT-A in women of AMA compared with FISH. Moreover, blastocyst biopsy seemed to be associated with a better outcome than polar body biopsy and cleavage-stage biopsy.


2020 ◽  
Author(s):  
Jacqueline A. Odgis ◽  
Katie M. Gallagher ◽  
Sabrina A. Suckiel ◽  
Katherine E. Donohue ◽  
Michelle A. Ramos ◽  
...  

Background: Increasingly, genomics is informing clinical practice, but challenges remain for medical professionals lacking genetics expertise, and in access to and clinical utility of genomic testing for minority and underrepresented populations. The latter is a particularly pernicious problem due to the historical lack of inclusion of racially and ethnically diverse populations in genomic research and genomic medicine. A further challenge is the rapidly changing landscape of genetic tests, and considerations of cost, interpretation and diagnostic yield for emerging modalities like whole genome sequencing. Methods: The NYCKidSeq project is a randomized controlled trial recruiting 1,130 children and young adults predominantly from Harlem and the Bronx with suspected genetic disorders in three disease categories: neurologic, cardiovascular, and immunologic. Two clinical genetic tests will be performed for each participant, either proband, duo or trio whole-genome sequencing (depending on sample availability) and proband targeted gene panels. Clinical utility, cost and diagnostic yield of both testing modalities will be assessed. This study will evaluate the use of a novel, digital platform (GUÍA) to digitize the return of genomic results experience and improve participant understanding for English- and Spanish-speaking families. Surveys will collect data at three study visits; baseline (0 months), results disclosure visit (ROR1, +3 months), and follow up visit (ROR2, +9 months). Outcomes will assess parental understanding of and attitudes towards receiving genomic results for their child and behavioral, psychological and social impact of results. We will also conduct a pilot study to assess a digital tool called GenomeDiver designed to enhance communication between clinicians and genetic testing labs. We will evaluate GenomeDiver's ability to increase the diagnostic yield compared to standard practices, to improve clinician's ability to perform targeted reverse phenotyping, and to increase the efficiency of genetic testing lab personnel. Discussion: The NYCKidSeq project will contribute to the innovations and best practices in communicating genomic test results to diverse populations. This work will inform strategies for implementing genomic medicine in health systems serving diverse populations using methods that are clinically useful, technologically savvy, culturally sensitive, and ethically sound.


2017 ◽  
Vol 53 ◽  
pp. 100-105 ◽  
Author(s):  
Tia L. Kauffman ◽  
Benjamin S. Wilfond ◽  
Gail P. Jarvik ◽  
Michael C. Leo ◽  
Frances L. Lynch ◽  
...  

2018 ◽  
Vol 218 (1) ◽  
pp. S161
Author(s):  
Bethany Mulla ◽  
Olivia H. Chang ◽  
Anna M. Modest ◽  
Michele R. Hacker ◽  
Karen F. Marchand ◽  
...  

Sign in / Sign up

Export Citation Format

Share Document